Development of Anti-TNF-Α Treatment Adherence Scale: Patients with Rheumatic Disease

• Published in: International journal of caring sciences Vol. 16; no. 2; pp. 829 - 839
• Main Authors: Ozkaraman, Ayse, Uzgor, Fusun, Atalay, Hatice Ozden, Bilge, Nazife Sule Yasar, Kasifoglu, Timucin
• Format: Journal Article
• Language: English
• Published: Nicosia Professor Despina Sapountzi - Krepia Publisher of the International Journal of Caring Sciences 01.05.2023
• Subjects: Arthritis; Drugs; Inflammatory diseases; Nurses; Outpatient care facilities; Patient compliance; Patients; Rheumatic diseases; Rheumatology; Tumor necrosis factor-TNF; Validity
• ISSN: 1791-5201; 1792-037X

Background: In recent years, there has been an increase in the use of anti-TNF-α therapies in the treatment of rhemnatological diseases. Aim: The aim of this study was to develop a subcutaneous anti-TNF-α treatment adherence scale and investigate and confirm the reliability and validity of this new instrument. This methodological study was performed in an university hospitals between April 2018 and March 2019. The sample of the study (n:165) consisted of individuals who were completed the first month of SC anti TNF-α treatment. The research data were collected by using an individual introduction form and the newly developed Anti TNF-α Treatment Adherence Scale. In the analysis of the data, the test-retest reliability analysis, validity analysis, factor analysis, structural equation model and internal consistency analysis were used. Results: The item-total test correlation values were determined to be between 0.33 and 0.71. In the fit index calculations, it was found that the Root Mean Square Error of Approximation was 0.10, Goodness of Fit Index was 0.999, Adjusted Goodness of Fit Index was 0.998, Comparative Fit Index was 0.926; and χ2 was 2.670 (p<0.001). Cronbach a coefficient was calculated as 0.690 for factor 1, 0.765 for factor 2, 0.628 for factor 3 and 0.671 for the overall scale. Conclusion: In this study. Anti TNF-α Treatment Adherence Scale was determined that it is a valid and reliable scale. It is the first assessment tool that can be used in the evaluation of drug adherence in SC Anti-TNF-α treatment performed by patients / their relatives due to rheumatologic and all inflammatory diseases.